| Literature DB >> 35091708 |
Carolina C S Valentim1, Justin C Muste1, Amogh I Iyer1, Michael A Krause2, Aneesha Kalur1, Steve W Gendi3, Marc Ohlhausen3, Aleksandra Rachitskaya1, Rishi P Singh1, Katherine E Talcott4.
Abstract
OBJECTIVES: To characterize the use of virtual visits, as well as compare the characteristics to in-person visits during the pandemic period.Entities:
Year: 2022 PMID: 35091708 PMCID: PMC8796604 DOI: 10.1038/s41433-022-01938-2
Source DB: PubMed Journal: Eye (Lond) ISSN: 0950-222X Impact factor: 3.775
Patient characteristics.
| Virtual visits ( | In-person visits ( | ||
|---|---|---|---|
| Female | 1458 (64.3) | 1538 (59.4) | |
| Male | 808 (35.7) | 1052 (40.6) | |
| 64.3 (±16.6) | 65.9 (±15.8) | ||
| White | 1601 (78.1) | 2035 (81.1) | |
| Black | 344 (16.8) | 326 (13.0) | |
| Asian | 20 (1.0) | 30 (1.2) | 0.57c |
| Multiracial | 26 (1.3) | 31 (1.2) | >0.99c |
| Other | 8 (0.4) | 8 (0.3) | 0.88c |
| Unavailable, declined and unknown | 50 (2.4) | 79 (3.1) | 0.18c |
| Medicare | 1054 (51.4) | 1393 (55.5) | |
| Medicaid | 148 (7.2) | 186 (7.4) | 0.85c |
| None | 20 (1.0) | 0 (0) | |
| Military | 6 (0.3) | 12 (0.5) | 0.45c |
| Private | 821 (40.1) | 918 (36.6) | |
| 58,357 (±20,192) | 56,273 (±18,354) | ||
a: Pearson’s chi-square test; b: t-test; c: proportion test.
Visit characteristics.
| Virtual visits ( | In-person visits ( | ||
|---|---|---|---|
| New | 221 (9.8) | 351 (13.6) | |
| Established | 2045 (90.2) | 2239 (86.4) | |
| Comprehensive | 785 (34.6) | 618 (23.9) | |
| Optometry | 443 (19.5) | 772 (29.8) | |
| Oculoplastics | 295 (13.0) | 74 (2.9) | |
| Cornea | 267 (11.8) | 378 (14.6) | |
| Glaucoma | 233 (10.3) | 162 (6.3) | |
| Retina/uveitis | 196 (8.6) | 449 (17.3) | |
| Neuro-ophthalmology | 40 (1.8) | 85 (3.3) | |
| Oncology | 7 (0.3) | 43 (1.7) | |
| Strabismus | 0 (0) | 9 (0.3) | * |
a: Pearson’s chi-square test; b: proportion test; * Inaccurate due to small sample size.
Virtual visits characteristics.
| Video ( | Phone ( | Hybrid ( | ||
|---|---|---|---|---|
| Female | 755 (68.6) | 663 (60.4) | 40 (58.8) | |
| Male | 345 (31.4) | 435 (39.6) | 28 (41.2) | |
| 61.1 (16.7) | 67.6 (16.1) | 71.8 (11.9) | ||
| 0.20c | ||||
| White | 872 (79.3) | 843 (76.8) | 58 (85.3) | 0.13d |
| Black | 168 (15.3) | 205 (18.7) | 7 (10.3) | |
| Asian | 11 (1.0) | 8 (0.7) | 2 (2.9) | * |
| Multiracial | 13 (1.2) | 16 (1.5) | 0 (0) | * |
| Other | 6 (0.5) | 3 (0.3) | 0 (0) | * |
| Unavailable, declined, and unknown | 30 (2.7) | 23 (2.1) | 1 (1.5) | * |
| Comprehensive | 308 (28.0) | 455 (41.4) | 22 (32.4) | |
| Optometry | 226 (20.5) | 217 (19.8) | 0 (0) | |
| Oculoplastics | 268 (24.4) | 27 (2.5) | 0 (0) | |
| Cornea | 120 (10.9) | 146 (13.3) | 1 (1.5) | |
| Glaucoma | 102 (9.3) | 124 (11.3) | 7 (10.2) | 0.29d |
| Retina/uveitis | 49 (4.5) | 109 (9.9) | 38 (55.9) | |
| Neuro-ophthalmology | 20 (1.8) | 20 (1.8) | 0 (0) | * |
| Oncology | 7 (0.6) | 0 (0) | 0 (0) | * |
a: Pearson’s chi-square test; b: t-test; c: Fisher’s exact test; d: proportion test; * Inaccurate due to small sample size.
Diagnoses categories across total and new diagnoses.
| Total diagnoses | New diagnoses | |||||
|---|---|---|---|---|---|---|
| Virtual visits ( | In-person visits ( | Virtual visits ( | In-person visits ( | |||
| Eyelids, lacrimal system, and orbit | 610 (26.9) | 184 (7.1) | 303 (47.4) | 102 (12.8) | ||
| Sclera, cornea, iris, and ciliary body | 279 (12.3) | 272 (10.5) | 0.052b | 51 (8.0) | 74 (9.3) | 0.45b |
| Glaucoma | 275 (12.1) | 331 (12.8) | 0.052b | 6 (0.9) | 51 (6.4) | |
| Intra-ocular lens related conditions | 184 (8.1) | 251 (9.7) | 0.062b | 7 (1.1) | 88 (11) | |
| Conjunctiva | 175 (7.7) | 70 (2.7) | 118 (18.5) | 46 (5.8) | ||
| Choroid and retina | 155 (6.8) | 500 (19.3) | 6 (0.9) | 67 (8.4) | ||
| Lens | 144 (6.4) | 337 (13) | 11 (1.7) | 121 (15.1) | ||
| Follow-up/Postop check | 100 (4.4) | 61 (2.4) | 1 (0.2) | 19 (2.4) | ||
| Other disorders of eye and adnexa | 86 (3.8) | 31 (1.2) | 49 (7.7) | 16 (2) | ||
| Systemic conditions | 73 (3.2) | 202 (7.8) | 27 (4.2) | 66 (8.3) | ||
| Vitreous and globe | 64 (2.8) | 128 (4.9) | 18 (2.8) | 66 (8.3) | ||
| Visual disturbances and blindness | 64 (2.8) | 56 (2.2) | 0.160b | 35 (5.5) | 33 (4.1) | 0.28b |
| Ocular muscles, binocular movement, accommodation, and refraction | 42 (1.9) | 148 (5.7) | 7 (1.1) | 42 (5.3) | ||
| Optic nerve and visual pathways | 15 (0.7) | 19 (0.7) | 0.899b | 0 (0) | 8 (1) | |
a: Pearson’s chi-square test; b: proportion test; c: Fisher’s exact test; * Inaccurate due to small sample size.
Disposition after virtual and in-person visits and characteristics of follow-up visits.
| Virtual visits ( | In-person visits ( | |
|---|---|---|
| Follow-up | 1640 (72.4) | 1821 (70.3) |
| PID | 360 (15.9) | 281 (10.8) |
| Referral to DOS | 108 (4.8) | 167 (6.4) |
| Referral to PCP/CS | 19 (0.8) | 0 (0) |
| Outpatient surgery | 135 (6.0) | 124 (4.8) |
| Ambulatory procedure | 4 (0.2) | 186 (7.2) |
| Virtual visits ( | In-person visits ( | |
| Completed | 1205 (73.5) | 848 (46.6) |
| Canceled | 76 (4.6) | 64 (3.5) |
| No show | 46 (2.8) | 38 (2.1) |
| Not scheduled | 170 (10.4) | 42 (2.4) |
| Future date | 143 (8.7) | 829 (45.5) |
| Virtual visits ( | In-person visits ( | |
| Virtual | 186 (15.4) | 23 (2.7) |
| In-person | 1019 (84.6) | 825 (97.3) |
| Same day | 7 (0.6) | 0 (0) |
| 1 day | 13 (1.1) | 9 (1.1) |
| 2–6 days | 62 (5.1) | 60 (7.1) |
| 1 week | 129 (10.7) | 164 (19.3) |
| 2–4 weeks | 332 (27.6) | 268 (31.6) |
| 5–25 weeks | 643 (53.4) | 330 (38.9) |
| 26 weeks or more | 19 (1.6) | 17 (2.0) |
Abbreviations: PID: provider-initiated discontinuity; DOS: different ophthalmology specialty; PCP: primary care practitioner; CS: clinical specialty.